Biogen (BIIB) Tops Q3 EPS by 68c; Announces Corp. Restructuring; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
October 21, 2015 7:31 AM EDTASCEND Phase 3 Trial Did Not Meet Primary and Secondary Endpoints; Natalizumab Demonstrated Statistically Significant Effect on Upper Limb Function in Patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary endpoints, Biogen (NASDAQ: BIIB) reported today. During the study, natalizumab was... More
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
October 21, 2015 7:30 AM EDTCorporate restructuring to result in an 11% workforce reduction
First patient enrolled in aducanumab Phase 3 studies for Alzheimers disease
Company announces agreement to license Mitsubishi Tanabe Pharmas Phase 3 ready molecule for autoimmune diseases
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2015 results, including revenues of $2.8 billion, an 11% increase compared to the third quarter of 2014. Non-GAAP diluted earnings per share (EPS) for the third quarter of 2015 were $4.48, an increase of 18% over the third quarter of 2014. Non-GAAP... More
